Literature DB >> 23892183

Models for open innovation in the pharmaceutical industry.

Alexander Schuhmacher1, Paul-Georg Germann, Henning Trill, Oliver Gassmann.   

Abstract

The nature of the pharmaceutical industry is such that the main driver for its growth is innovation. In view of the vast challenges that the industry has been facing for several years and, in particular, how to manage stagnating research and development (R&D) productivity, pharmaceutical companies have opened their R&D organizations to external innovation. Here, we identify and characterize four new types of open innovator, which we call 'knowledge creator', 'knowledge integrator', 'knowledge translator' and 'knowledge leverager', and which describe current open R&D models.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Mesh:

Year:  2013        PMID: 23892183     DOI: 10.1016/j.drudis.2013.07.013

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  13 in total

Review 1.  Malaria medicines: a glass half full?

Authors:  Timothy N C Wells; Rob Hooft van Huijsduijnen; Wesley C Van Voorhis
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

2.  Outcubation--where incubation meets outsourcing.

Authors:  Ulrich A K Betz; Christian A Tidona
Journal:  Nat Biotechnol       Date:  2015-01       Impact factor: 54.908

Review 3.  Lost but making progress--Where will new analgesic drugs come from?

Authors:  David Borsook; Richard Hargreaves; Chas Bountra; Frank Porreca
Journal:  Sci Transl Med       Date:  2014-08-13       Impact factor: 17.956

Review 4.  Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.

Authors:  Maria Angeles Martinez-Grau; Maria Alvim-Gaston
Journal:  Pharmaceut Med       Date:  2019-06

5.  Sources of Information as Determinants of Product and Process Innovation.

Authors:  Jaime Gómez; Idana Salazar; Pilar Vargas
Journal:  PLoS One       Date:  2016-04-01       Impact factor: 3.240

6.  Dynamic Collaborations for the Development of Immune Checkpoint Blockade Agents.

Authors:  Arisa Djurian; Tomohiro Makino; Yeongjoo Lim; Shintaro Sengoku; Kota Kodama
Journal:  J Pers Med       Date:  2021-05-24

Review 7.  Increasing efficiency in vaccine Production: A primer for change.

Authors:  Ole Kristian Aars; Michael Clark; Nina Schwalbe
Journal:  Vaccine X       Date:  2021-06-16

Review 8.  Research and development in drug innovation: reflections from the 2013 bioeconomy conference in China, lessons learned and future perspectives.

Authors:  Changxiao Liu; Panayiotis P Constantinides; Yazhuo Li
Journal:  Acta Pharm Sin B       Date:  2014-02-18       Impact factor: 11.413

9.  A crystallographic perspective on sharing data and knowledge.

Authors:  Ian J Bruno; Colin R Groom
Journal:  J Comput Aided Mol Des       Date:  2014-08-05       Impact factor: 3.686

Review 10.  Changing R&D models in research-based pharmaceutical companies.

Authors:  Alexander Schuhmacher; Oliver Gassmann; Markus Hinder
Journal:  J Transl Med       Date:  2016-04-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.